louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02817321: Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain of Hepatectomy With Right J-shape Subcostal Incision
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatectomy
Analgesia
Nerve Block
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2016-06-29
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This prospective, randomized study,control study aims to compare the analgesic effect,opioids consumption,quality of recovery,length of hospital stay and incidence of chronic pain,et al. single-injection TPVB +continuous(pulsatile infusion) TPVB and intravenous patient-controlled analgesia (IPCA) alone in patients undergoing hepatectomy with right J-shape subcostal incision.


Eligibility criteria: Inclusion Criteria:

* Age 18-70 yrs
* American Society of Anesthesiologists physical statusⅠ-Ⅲ
* Undergo hepatectomy with J-shape subcostal incision
* Informed consent

Exclusion Criteria:

* A known allergy to the drugs being used
* Coagulopathy, on anticoagulants
* Analgesics intake, history of substance abuse
* Participating in the investigation of another experimental agent
* Inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)

Primary outcomes:
measure: cumulative morphine consumption
timeFrame: within 48 postoperative hours
Secondary outcomes:
measure: The pain scores determined by the numeric rating scale (NRS, 0-10)
timeFrame: At 0, 2,4, 8, 12, 24 ,48,72hours and 7day after the surgery
measure: nausea and vomiting score
timeFrame: At 0, 2,4, 8, 12, 24 and 48hours after the surgery
measure: pruritus score
timeFrame: At 0, 2,4, 8, 12, 24 and 48hours after the surgery
measure: ambulation time
timeFrame: within the 7 days after surgery
measure: time of recovery of bowl movement
timeFrame: within the 7 days after surgery
measure: Postoperative hospital length of stay
timeFrame: Up to 4 weeks
measure: patient satisfaction with anesthesia
timeFrame: 48 hours after surgery
measure: data collection of chronic pain
timeFrame: at 3,6,12 months after surgery
Other outcomes:
Locations:
city: Beijing
country: China
facility: Xulei CUI
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Yuguang Huang, MD.
role: STUDY_CHAIR
References:
Clinical trial NCT01578421: Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser
Official title: Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Failure Chronic Requiring Hemodialysis
Lead sponsor: Kantonsspital Aarau
Sponsor class: OTHER
Collaborators: name: Fresenius Medical Care Deutschland GmbH
First posted: 2012-04-17
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare clearance and removal rates of phosphate, ß2-microglobulin (ß2-m) and leptin and albumin loss with different dialyser membranes during post-dilution online hemodiafiltration.


Eligibility criteria: Inclusion Criteria:

* hemodialysis patients 18 years and older
* treated by post dilution on-line Hemodiafiltration (HDF) for at least one month
* who reached a dialysis dose (Kt/V) of at least 1.2 at each of the last two monthly checks
* who are on a stable anticoagulation and anemia management
* whose hemoglobin is between 10.5 and 13.0 g/dl
* who are clinically stable based on judgment of nephrologist
* who are on a regular thrice weekly HDF schedule, e.g. Monday-Wednesday-Friday or Tuesday-Thursday-Saturday,
* who have a good vascular access (fistula or graft) which enables easy insertion of the needles and suitable effective blood flow (\> 300 ml/min)
* who are able to understand the nature and requirements of the clinical investigation and who have given written informed consent

Exclusion Criteria: Patients

* with active Hepatitis B, Hepatitis C or HIV infection
* who are severely malnourished as judged by the principal investigator
* who are known or suspected to have allergy to the trial products or related products
* with a central venous catheter based vascular access
* who are abusing non-legal drugs or alcohol
* who have currently active malignant disease
* who are female of child-bearing age without effective measures of contraception, pregnant or breastfeeding
* who participate simultaneously in another clinical investigation
* who have participated in othe clinical investigations during the last month
* who are uncooperative

Primary outcomes:
measure: Clearance and removal rate of phosphate, beta2 microglobulin and leptin
timeFrame: 4 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Aarau
country: Switzerland
facility: Nephrology Division, Kantonsspital Aarau
Study officials:
affiliation: Nephrology Division, Kantonsspital Aarau
name: Andreas Bock, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06502821: Preferences of Israeli New Physiotherapists in Choosing Their Future Workplace
Official title: Preferences of Israeli New Physiotherapists in Choosing Their Future Workplace
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Workplace
Lead sponsor: University of Haifa
Sponsor class: OTHER
First posted: 2024-07-16
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: students for physical therapy, during their 4th year of studying, and experienced physical therapists

Brief summary: This study aim to create a multidimensional body of knowledge on the factors influencing physiotherapy graduates in Israel in choosing a workplace, satisfaction with the chosen framework, and intergenerational differences in these factors. In addition, to examine the relationship between the factors for choosing a professional career in physiotherapy and choosing a workplace

Detailed description: The study will be mixed methods and will include: focus groups for the accuracy of the content of the questionnaires (5 students, 5 physiotherapists), a preliminary study to examine the clarity and understanding of the questionnaires (10 students,20 physiotherapists), and a cross-sectional study using online questionnaires to examine workplace preferences and the factors influencing choosing a career in physiotherapy among fourth-year students, young physiotherapists and experienced physiotherapists.

Eligibility criteria: Inclusion Criteria:

* physiotherapists

Exclusion Criteria:

-

Primary outcomes:
measure: choosing a profession
timeFrame: baseline
measure: choosing workplace
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Haifa University, Department of PHysical Therapy
Study officials:
affiliation: University of Haifa
name: Gali Dar, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01838421: Correlation of the Paediatric Tracheal Tube Size
Official title: Correlation of the Paediatric Tracheal Tube Size With the Known Formulas for the Calculation of the Size
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pediatric Tracheal Tube Size
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2013-04-24
Enrollment: 3000
Sex: ALL
Minimum age (years): 1
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children under the age of 12 who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12

Brief summary: In the context of the study a retrospective data collection of all anaesthesia protocols of children under the age of 12 which underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011 and 2012 shall be executed. The correlation of the tracheal tube sizes with the weight, age and height shall be evaluated. This data collection should serve to reevaluate the already published formulas e.g. (Rettberg M. et al., 2011).


Eligibility criteria: Inclusion Criteria:

* Children under the age of 12 who underwent surgery in the Charité - University Medicine Berlin, Charité Campus Virchow - Klinikum in the years 2011/12

Exclusion Criteria:

* No endotracheal tube inserted

Primary outcomes:
measure: Correlation of the tracheal tube size with the known formulas for the calculation of the size. Correlation of the tracheal tube size with the known formulas for the calculation of the size
timeFrame: 24 month data capture
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charité - University Medicine
Study officials:
affiliation: Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charité - University Medicine Berlin
name: Claudia Spies, MD Prof.
role: STUDY_CHAIR
References:
citation: von Rettberg M, Thil E, Genzwurker H, Gernoth C, Hinkelbein J. [Endotracheal tubes in pediatric patients. Published formulas to estimate the optimal size]. Anaesthesist. 2011 Apr;60(4):334-42. doi: 10.1007/s00101-010-1756-0. German.
Clinical trial NCT02368821: From Cytotrophoblast to Syncytiotrophoblast
Official title: From Cytotrophoblast to Syncytiotrophoblast - Telomere Length, Aggregate Formation and Senescence in Placenta From Complicated Pregnancies Compare to Placenta From Normal Pregnancies.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Syncytiotrophoblast
Keywords: cytotrophoblast
syncytiotrophoblast
placentas
intrauterine growth restriction
preeclampsia
placenta accrete
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2015-02-23
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: placentas from normal and complicated pregnancy

Brief summary: A deeper understanding of the syncytiotrophoblast development processes and its properties may allow a better understanding of the placenta pathological process for the development of treatment models for the relevant pregnancy complications.The aim of this study is to compare telomere length, aggregate formation, and senescence markers in placentas from complicated pregnancy with placentas from normal pregnancy.

Detailed description: Protocol summary No. 2 for research 0202-14 of date: 22/11/2014. Rationale for the research A deeper understanding of the syncytiotrophoblast development processes and its properties may allow a better understanding of the placenta pathological process for the development of treatment models for the relevant pregnancy complications.

The aim of this study is to compare telomere length, aggregate formation, and senescence markers in the syncytiotrophoblast of placentas from complicated pregnancy with placentas from normal pregnancy.

Telomere lenght and aggregate formation will be assessed by the fluorescent intensity of telomere FISH.

Senescence will be assessed by immunohistochemistry for the markers - SAHF, cyclin dependent kinase inhibitors p16/p21, HLAX, ERVWE1, SA-B-gal.

The study groups

1. A retrospective arm - paraffin blocks which were collected over the years from placentas from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete) will be compared to blocks of placentas from normal pregnancies.
2. The prospective arm - placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete) . Will be compared to placentas of normal pregnancies.
3. A laboratory model based on human placenta cell cultures

Eligibility criteria: Inclusion Criteria:

* placentas from normal and complicated pregnancy

Exclusion Criteria:

* women consent

Primary outcomes:
measure: Length of telomere and senescence markers amount in the placentas.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02047721: The Effects of Exercise on Appetite Regulation in Overweight/Obese Individuals
Official title: The Effects of Exercise on Appetite Regulation in Overweight/Obese Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: American Diabetes Association
First posted: 2014-01-28
Enrollment: 69
Sex: ALL
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: In this study the Investigators are examining the effects of a 12-week exercise program (intervention) on measures of appetite and food intake regulation in overweight to mildly obese healthy adults. The Investigators hypothesize that individuals who lose a significant amount of weight in response to the intervention will show a reduction in the brain response to food cues as measured by functional magnetic resonance imaging (fMRI) when compared to those who do not lose weight. These changes in neuronal activity will be associated to physiologic and behavioral measures.


Eligibility criteria: Inclusion Criteria:

* all ethnic groups and both genders;
* age: 21-45 yrs;
* BMI: 27-35;
* weight stable within +/- 5 percent in the last 6 months;
* sedentary (less than 1 hour of planned physical activity by self-report).

Exclusion Criteria:

* history of cardiovascular disease (CVD), diabetes mellitus, uncontrolled hypertension, untreated thyroid disease, renal disease, hepatic disease, or any other medical condition affecting weight or energy metabolism;
* unable to effectively exercise due to cardiac, pulmonary, neurologic or orthopedic reasons;
* unable to pass screening graded exercise treadmill test;
* currently smoking;
* medications affecting weight, Energy Intake (EI) or Energy Expenditure (EE) in the last 6 months;
* weight loss or weight gain of \>5 percent in past 6 months;
* currently pregnant, lactating or less than 6 months post-partum;
* bariatric surgery;
* major psychiatric disorder, presence of alcohol or substance abuse, current depression by history and/or a score \>21 on the he Center for Epidemiologic Studies Depression Scale (CES-D), history of eating disorders and/or a score of \>20 on the EATS-26;
* contraindication to MRI

Primary outcomes:
measure: fMRI Response to Visual Food Cues
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Univeristy of Colorado
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Kristina Legget, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00581321: Oral Water Ingestion in Heart Transplant Patients
Official title: Acute Hemodynamic Effects of Oral Water in a Stable Cardiac Transplant Population
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Blood Pressure
Cardiac Transplantation
Keywords: water
blood pressure
vascular resistance
cardiac transplantation
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: National Center for Research Resources (NCRR)
First posted: 2007-12-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: In this study the investigators propose to assess the hemodynamic response to the ingestion of 16 fl oz of water. The investigators will test the hypothesis that water ingestion will increase the systemic vascular resistance.

Detailed description: In this study we propose to assess the hemodynamic response to the ingestion of 16 fl oz of water. We will test the hypothesis that water ingestion will increase the systemic vascular resistance. This study will occur in patients status post cardiac transplantation during their clinical right heart catheterizations. Invasive hemodynamics including cardiac outputs and plasma norepinephrine levels will be measured before and 30 min after the water ingestion.

Eligibility criteria: Inclusion Criteria:

* s/p cardiac transplantation scheduled for clinical right heart catheterization
* age \> 18 years

Exclusion Criteria:

* significant tricuspid regurgitation
* inability to safely swallow 500 ml of water
* other major medical comorbidities such as advanced renal disease where water ingestion may be harmful to patient

Primary outcomes:
measure: change in total vascular resistance
timeFrame: 40 min (before to 30 min after water ingestion
Secondary outcomes:
measure: blood pressure
timeFrame: 40 min
measure: heart rate
timeFrame: 40 min
measure: plasma norepinephrine
timeFrame: 40 minutes
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Tennessee Valley Health Systems (Nashville VA)
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Satish R Raj, MD, MSCI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00687921: F18-Flouride PET/CT in Acute Knee Injury
Official title: F18-Flouride PET/CT in Acute Knee Injury. A Prospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Knee Injury
Keywords: Knee trauma
MRI
arthroscopy
Patients over the age of 18 who had knee trauma intent to or had MRI assessment scheduled for arthroscopy
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-06-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy

Brief summary: 18F-fluoride is a positron-emitting bone-seeking agent with favorable pharmacokinetic properties. Its uptake mechanism resembles that of 99mTc-MDP. After IV administration, 18F-fluoride diffuses through the bone capillaries into the bone extracellular fluid (ECF). Its plasma clearance is more rapid than that of 99mTc-MDP and its single-passage extraction efficiency is higher. The fast blood clearance of 18F-fluoride results in a better target- to- background ratio. Bone uptake of 18F-fluoride is two-fold higher than that of 99mTc-MDP. Combining the favorable pharmacokinetic characteristics of 18F-fluoride with the high performance of PET technology, 18F-fluoride is a valuable imaging modality of the skeleton.

There are only few manuscripts on the role of static 18F-fluoride PET for detection of lesions in patients referred for non-oncologic indications The purpose of the study is to prospectively assess the added value of Fluoride PET/CT in the clinical setting of acute knee injury. The findings of Fluoride PET/CT will be correlated with those found on arthroscopy and MRI which the currently used diagnostic techniques with a high, however, not perfect diagnostic accuracy regarding the issue of bone injury which is a critical component on the long term outcome after knee injury.

Detailed description: We intend to inject only 5mCi of Fluoride, as we already did before, thus reducing the radiation exposure to half of that of the routine Tc-MDP bone scintigraphy.

We will refer 50 patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy. The compartments of the injured knee will be evaluated on each of the modalities.

Exclusion criterion is pregnancy

Eligibility criteria: Inclusion Criteria:

* patients over the age of 18 who had knee trauma

Exclusion Criteria:

* pregnancy
* age under 18 years

Primary outcomes:
measure: we will refer patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy. The compartments of the injured knee will be evaluated on each of the modalities.
timeFrame: 6 mounth
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: Einat R. Even-Sapir, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00945321: A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
Official title: A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chemotherapy-Induced Nausea and Vomiting
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-07-24
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.


Eligibility criteria: Inclusion Criteria:

* Subject is in good health
* Subject is a nonsmoker
* Subject is willing to comply with the study restrictions

Exclusion Criteria:

* Subject has a history of any illness that might confound the results of the study or might make participation in the study unsafe
* Subject has a history of stroke, seizures, or major neurological disorder
* Subject has a history of cancer
* Subject consumes more than two alcoholic drinks per day
* Subject consumes more than three caffeinated beverages daily

Primary outcomes:
measure: Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg
timeFrame: Through 72 Hours Postdose
measure: Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg.
timeFrame: Through 72 Hours Postdose
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Shadle CR, Murphy MG, Liu Y, Ho M, Tatosian D, Li SX, Blum RA. A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects. Clin Pharmacol Drug Dev. 2012 Jul;1(3):93-101. doi: 10.1177/2160763X12447304.